About - Purilogics

We simplify and accelerate early-stage cell and gene therapy development.

Purilogics develops industry-leading membrane technologies for the biopharmaceutical industry. Our proprietary products are designed for use in research & early-stage development laboratories, to support market entry where rapid drug purification is essential to discovery.

Our Mission

Our goal is to help sector specialists get biologics to market faster, where they are needed to support the large and growing population of patients with long-term, chronic conditions such as cancers, cardiovascular diseases, and autoimmune disorders.

Our Story

Founded by Drs. Scott Husson and Jinxiang Zhou in 2013, in Greenville, South Carolina, the idea for the company was inspired by research from over a decade of investigation at Clemson University.

Purchased in 2022 by Donaldson as a part of their new Life Sciences focus, Purilogics develops and produces best-in-class membrane technologies for the rapidly growing biopharmaceutical industry.

Our proprietary products are designed for use in research & early-stage development laboratories, to support market entry where rapid drug purification is essential to discovery.

We are proud to collaborate with

The newly defined Donaldson Life Sciences division is building a portfolio of biopharma innovations to provide cutting-edge technologies that simplify and accelerate development and production of therapeutics.

We are leveraging Donaldson’s over 100 year legacy as a world leader in providing filtration solutions and customer-centric service. We solve the world's most complex filtration challenges, and now are working to revolutionize solutions for biopharmaceutical applications.

Our strategy is underpinned by developing critical filtration, purification, and separation technologies that service the discovery, development, and GMC production of biopharmaceuticals. Isolere Bio, Purilogics, Solaris Biotech, and Univercells Technologies work together to provide differentiated solutions for genetic medicine bioprocessing while also consolidating multiple steps in the bioprocessing value-chain. We work with you, innovate, and deliver.

Our Team

In 2022 Purilogics became a part of a much larger team. We are excited that Donaldson Company, Inc. (NYSE: DCI), a leading worldwide provider of innovative filtration products and solutions is helping us to change how biologics production happens and come to market.

Jinxiang Zhou, PhD
Business Director

Jinxiang (Jin) is an inventor and co-founder of Purilogics. Jin is a graduate from National Science Foundation Innovation-Corps program, and he is an internationally recognized expert in the field of polymeric thin-film composite membranes.

Jin has spent 10+ years developing high-performance membranes and processes for chemical and biologic purification. Jin's leadership has included service as Vice President at Purilogics managing the company’s day-to-day operation, and Principal Investigator on multiple Purilogics small business innovation research (SBIR) grants to build high capacity and high selectivity membrane chromatography products for biologic purification. Jin earned PhD in Chemical Engineering from Clemson University.